Is RECEF or EQR a better dividend investment in 2026?

RECEF currently yields 909.09% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: RECEF offers higher current income.

What is the dividend yield difference between RECEF and EQR?

RECEF has a forward dividend yield of 909.09% ($2.00/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 904.36 percentage points.

Home › Compare › RECEF vs EQR

RECEF vs EQR: Dividend Comparison 2026

RECEF yields 909.09% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RECEF wins by $8252648.17M in total portfolio value

INVESTMENT

TIME HORIZON10 years

RECEF

● Live price

909.09%

Share price

$0.22

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8252648.21M

Annual income

$6,784,560,004,057.53

Full RECEF calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — RECEF vs EQR

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	RECEF	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, RECEF + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

RECEF pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF

Annual income on $10K today (after 15% tax)

$77,272.73/yr

After 10yr DRIP, annual income (after tax)

$5,766,876,003,448.90/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, RECEF beats the other by $5,766,876,000,202.23/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + EQR for your $10,000?

RECEF: 50%EQR: 50%

100% EQR50/50100% RECEF

Portfolio after 10yr

$4126324.13M

Annual income

$3,392,280,003,938.57/yr

Blended yield

82.21%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RECEF

No analyst data

Altman Z

-148.3

Piotroski

1/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys

EQR buys

No recent congressional trades found for RECEF or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricRECEFEQR

Forward yield	909.09% ✓	4.73%
Annual dividend / share	$2.00	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$8252648.21M ✓	$40.5K
Annual income after 10y	$6,784,560,004,057.53 ✓	$3,819.61
Total dividends collected	$8138900.96M ✓	$16.9K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: RECEF vs EQR ($10,000, DRIP)

Year	RECEF Portfolio	RECEF Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$101,609	$90,909.09	$11,248	$547.57	+$90.4K → RECEF
2	$972,011	$863,288.79	$12,701	$666.53	+$959.3K → RECEF
3	$8,758,157	$7,718,105.75	$14,405	$814.59	+$8.74M → RECEF
4	$74,364,546	$64,993,317.91	$16,413	$999.84	+$74.35M → RECEF
5	$595,318,755	$515,748,691.06	$18,795	$1,232.92	+$595.30M → RECEF
6	$4,495,664,203	$3,858,673,134.79	$21,639	$1,527.95	+$4495.64M → RECEF
7	$32,043,550,537	$27,233,189,840.42	$25,057	$1,903.80	+$32043.53M → RECEF
8	$215,696,715,677	$181,410,116,602.38	$29,197	$2,385.87	+$215696.69M → RECEF
9	$1,372,045,052,584	$1,141,249,566,809.58	$34,250	$3,008.70	+$1372045.02M → RECEF
10	$8,252,648,210,323	$6,784,560,004,057.53	$40,467	$3,819.61	+$8252648.17M → RECEF

RECEF vs EQR: Complete Analysis 2026

RECEF — Stock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this RECEF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHD RECEF vs JEPI RECEF vs O RECEF vs KO RECEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.